Title:Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019)
Volume: 27
Issue: 26
Author(s): Chahinez Houacine*, Iftikhar Khan and Sakib Saleem Yousaf*
Affiliation:
- School of Pharmacy and Biomedical Sciences, Faculty of Clinical and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE,United Kingdom
- School of Pharmacy and Biomedical Sciences, Faculty of Clinical and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE,United Kingdom
Keywords:
Resveratrol, cardiovascular disease, bioavailability, nanotechnology, DDS, resveratrol.
Abstract: With a 2030 projection of 23.6 million deaths per year, the prevalence and severity of cardiovascular
disease are astoundingly high. Thus, there is a definitive need for the identification of novel compounds with
the potential to prevent or treat the disease and associated states. Moreover, there is also an ever-increasing
need for drug delivery systems (DDS) that cope with poor and ranging physiochemical properties of therapeutic
compounds to achieve the clinical effect. The usage of resveratrol (RES) is a growing area of interest with innumerate
pieces of research, evidencing the drug’s efficacy. This drug is, however, marred; its notably poor physiochemical
properties (namely poor water solubility) limit its use for oral drug delivery. RES analogues, however,
potentially possess superior physiochemical characteristics offering a remedy for the aforementioned
drawback. However, particulate based DDS are equally able to offer property amelioration and targeting. This
review offers an extensive examination into the role of RES as a potential cardioprotective agent. The prevalence
and suitability of associated analogues and the role of nanotechnology in overcoming physicochemical
boundaries, particularly through the development of nanoparticulate formulations, will be discussed in detail.
